{
    "clinical_study": {
        "@rank": "3045", 
        "arm_group": {
            "arm_group_label": "Cyclophosphamide, Ipilimumab", 
            "arm_group_type": "Experimental", 
            "description": "Treatment:\nCyclophosphamide 300 mg/m2 po - Day 1 of Weeks 1, 4, 7, and 10, for a total of 4 doses; (premedication prior to each dose of Cyclophosphamide 8mg Zofran po, then prn)\nIpilimumab 10 mg/kg iv - Day 3 of Weeks 1, 4, 7, and 10 for a total of 4 doses Maintenance treatment will be given on Weeks 24, 36, and 48 Ipilimumab 10 mg/kg iv"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to see whether the combination of low-dose Cyclophosphamide and\n      Anti-CTLA4 (Ipilimumab) will stop tumor growth in patients with advanced skin cancer. The\n      investigators expect to see an increase in response rate of the combination over Anti-CTLA-4\n      alone and estimate a response rate of approximately 20 % in the proposed population."
        }, 
        "brief_title": "CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma", 
        "completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "detailed_description": {
            "textblock": "The transient removal of CTLA-4-mediated inhibition (CTLA-4 blockade) can induce effective\n      anti-tumor immunity. Efficacy of CTLA-4 blockade as a single agent has been shown in\n      melanoma 53. It has been hypothesized that anti-CTLA-4 antibody might deplete Treg cells 54,\n      inducing autoimmunity. However, patients receiving Ipilimumab have not shown a decrease in\n      Treg number or function in peripheral blood 55.\n\n      This trial will answer the question if the combination of Anti-CTLA 4 (following a well\n      established regimen of Ipilimumab) and Cyclophosphamide (given at immunomodulatory doses)\n      will result in antitumor activity in patients with metastatic melanoma due to synergistic\n      immunomodulating effects by overcoming tolerance."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Men & women, ages \u226518\n\n          2. Willing/able to give written informed consent.\n\n          3. Histologic diagnosis of unresectable AJCC Stage III/IV malignant melanoma\n\n          4. At least 2wks must have elapsed since last chemotherapy, immunotherapy, hormonal\n             therapy, radiotherapy or major surgery & beginning of protocol therapy. At least 6wks\n             for nitrosoureas, mitomycin C, & liposomal doxorubicin\n\n          5. Toxicity related to prior therapy must either have returned to \u2264 grade 1 or baseline.\n\n          6. Two punch tumor biopsy at Screening and Wk12 (4mm diameter) must be provided for\n             immune analysis/staining if patients have accessible disease.  Biopsies are optional\n             during the Maintenance Period.Site of tumor biopsy s/n be only site of measurable\n             disease. Minimum of 5 out of 1st 10 patients in stage I of the protocol must have\n             biopsy accessible disease.\n\n          7. Patients must have measurable disease defined as @ least 1 lesion that can be\n             accurately measured in @ least 1 dimension (longest diameter to be recorded) as >20\n             mm with conventional techniques or as >10 mm with spiral CT scan.\n\n          8. Required values for initial laboratory tests:\n\n               1. WBC \u2265 2000/uL\n\n               2. ANC \u2265 1000/uL\n\n               3. Platelets \u2265 50 x 103/uL\n\n               4. Hemoglobin \u2265 9.5 g/dL\n\n               5. Creatinine \u2264 3.0 x ULN\n\n               6. AST/ALT \u2264 2.5 x ULN for patients without liver metastasis, \u2264 5 x ULN for\n                  patients with liver metastasis\n\n               7. Bilirubin \u2264 3.0 x ULN, (except patients with Gilbert's Syndrome, who  must have\n                  a total bilirubin less than 3.0 mg/dL)\n\n          9. Life expectancy of at least 4mos\n\n         10. Patients w/stable, treated central nervous system (CNS) metastasis are eligible\n\n         11. ECOG Performance Status Score 0-1\n\n         12. Women of childbearing potential (WOCBP) must be using an adequate method of\n             contraception to avoid pregnancy throughout study & for up to 26wks after the last\n             dose of investigational product, in such a manner that the risk of pregnancy is\n             minimized.\n\n             WOCBP include any female who has experienced menarche and who has not undergone\n             successful surgical sterilization (hysterectomy, bilateral tubal ligation, or\n             bilateral oophorectomy) or is not post-menopausal. Post-menopause is defined as:\n\n               -  Amenorrhea \u2265 12 consecutive months w/o another cause, or\n\n               -  For women with irregular menstrual periods and taking hormone replacement\n                  therapy (HRT), documented serum follicle-stimulating hormone (FSH) level \u2265 35\n                  mIU/mL.\n\n               -  Women who are using oral contraceptives, other hormonal contraceptives (vaginal\n                  products/skin patches/implanted/injectable products), mechanical products such\n                  as an intrauterine device or barrier methods (diaphragm/condoms/ spermicides) to\n                  prevent pregnancy,are practicing abstinence or where their partner is sterile\n                  (eg vasectomy) should be considered to be of childbearing potential.\n\n               -  WOCBP must have a negative urine or serum pregnancy test (minimum sensitivity 25\n                  IU/L or equivalent units of HCG) w/in 72hrs before the start of ipilimumab.\n\n         13. Men of fathering potential must be using an adequate method of contraception to avoid\n             conception throughout the study [and up to 26wks after last dose of investigational\n             product] in a way that risk of pregnancy is minimized.\n\n        Exclusion Criteria:\n\n          1. Any other malignancy from which patient has been disease-free for less than 5yrs,\n             with the exception of adequately treated & cured basal or squamous cell skin cancer,\n             superficial bladder cancer or carcinoma in situ of the cervix.\n\n          2. Autoimmune disease: Patients with a history of inflammatory bowel disease, including\n             ulcerative colitis and Crohn's Disease, are excluded from this study, as are patients\n             with a history of symptomatic disease (eg rheumatoid arthritis, systemic progressive\n             sclerosis [scleroderma], systemic lupus erythematosus, autoimmune vasculitis [eg\n             Wegener's Granulomatosis]); motor neuropathy considered of autoimmune origin (eg\n             Guillain-Barre Syndrome and Myasthenia Gravis).\n\n          3. Any underlying medical or psychiatric condition, which in the opinion of investigator\n             will make administration of ipilimumab hazardous or obscure interpretation of AEs,\n             like a condition associated with frequent diarrhea.\n\n          4. Uncontrolled or significant cardiovascular disease\n\n          5. Any non-oncology vaccine therapy used for prevention of infectious diseases (for up\n             to 1mo before/after any dose of ipilimumab).\n\n          6. History of prior treatment with ipilimumab or prior CD137 agonist or CTLA 4 inhibitor\n             or agonist.\n\n          7. Concomitant therapy with any of following: IL 2, interferon, other non-study\n             immunotherapy regimens; immunosuppressive agents; other investigation therapies; or\n             chronic use of systemic corticosteroids (>60mg prednisone/day).\n\n          8. Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for\n             treatment of either a psychiatric or physical (eg infectious) illness.\n\n          9. Women of childbearing potential (WOCBP), defined above who:\n\n               1. are unwilling/unable to use an acceptable method of contraception to avoid\n                  pregnancy for their entire study period and for at least 26wks after cessation\n                  of study drug, or\n\n               2. have a positive pregnancy test at baseline, or\n\n               3. are pregnant or breastfeeding.\n\n         10. Persons of reproductive potential who are unwilling to use an adequate method of\n             contraception throughout treatment & for at least 26wks after ipilimumab is stopped."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "29", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 29, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01740401", 
            "org_study_id": "08-210", 
            "secondary_id": "114660"
        }, 
        "intervention": {
            "arm_group_label": "Cyclophosphamide, Ipilimumab", 
            "description": "This study consists of a Treatment Period, D1 Zofran 8mg pre-Cyclophosphamide 300mg/mg2 po and D3 Ipilimubab 10mg/kg iv wks 1,4,7 and 10; Tumor assessment at week 12; Follow-Up period weeks 13,16,and 20 with no treatment; Maintenance Period, D1 10mg/kg iv wks 24,36,48 and 60. Week 40=end of treatment; week 60=end of study", 
            "intervention_name": "Cyclophosphamide,  Ipilimumab", 
            "intervention_type": "Drug", 
            "other_name": [
                "Ipilimumab (BMS-734016, MDX010, MDX-CTLA4)", 
                "Cytoxin"
            ]
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Cyclophosphamide", 
                "Cytotoxic T-lymphocyte antigen 4"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Melanoma", 
            "Advanced Malignant Melanoma", 
            "Anti CTLA4 Blockade", 
            "Progression Free Survival", 
            "Interventional Therapy", 
            "Phase II Clinical Trial", 
            "Immunotherapy", 
            "T Cell Activation"
        ], 
        "lastchanged_date": "October 31, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10016"
                }, 
                "name": "New York University Langone Clinical Cancer Center"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase II Study of CTLA-4 Blockade and Low Dose Cyclophosphamide in Patients With Advanced Malignant Melanoma", 
        "other_outcome": {
            "description": "One of the tumor punch biopsy will be put in formalin for paraffin-embedding. The other tumor punch biopsy will be processed to obtain lysates to be used as antigens for the T cell assays.", 
            "measure": "Tumor-specific T cell responses will be measured in a subset of patients who have biopsy accessible tumor and have tumor biopsies taken.", 
            "safety_issue": "No", 
            "time_frame": "Two tumor punch biopsies (4mm in diameter) will be obtained before and after therapy (baseline and week 12, and optional during weeks 24, 36, and 48) if patients have accessible tumors."
        }, 
        "overall_official": {
            "affiliation": "New York University Langone Medical Center", 
            "last_name": "Nina Bhardwaj, MD,PhD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Objective response rate (ORR) using mWHO RC Safety (CTEP v4.0; NCI CTCAE criteria) 2-stage design - 10 patients will be enrolled in Stage 1. The primary endpoint will be assessed when 10 patients have been followed for 12 weeks. In order to continue the study uninterrupted, additional patients will be enrolled in Stage 2 of the study, provided that safety does not become an issue. However, it is estimated that no more than 6 patients will be enrolled before the primary endpoint can be assessed in the initial 10 patients of the study.", 
            "measure": "The primary objective of this study is:  Evaluate the anti-tumor activity of the combination of low dose Cyclophosphamide and CTLA-4 blockade using Objective Response Rate (ORR) by 12 weeks following mWHO RC.", 
            "safety_issue": "Yes", 
            "time_frame": "12 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01740401"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Bhardwaj, Nina, M.D.", 
            "investigator_full_name": "Dr. Nina Bhardwaj", 
            "investigator_title": "Director, Tumor Vaccine Program", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Peripheral blood taken at baseline/various therapeutic time points/possibly maintenance cycles to evaluate T regulatory cells identified, serially monitored by polychromatic flow cytometry using FoxP3+/CD4+/CD127low/CD25hi markers.", 
            "measure": "The secondary objectives are: 1. Progression-free survival 2. T regulatory cell profile in peripheral blood", 
            "safety_issue": "No", 
            "time_frame": "Progression-free survival is measured from date of entry to date of 1st documented evidence of recurrence, confirmation of PD, or death (whichever is 1st). T regulatory cells are measured on D1 (pre CTX) & D3 of each cycle."
        }, 
        "source": "Bhardwaj, Nina, M.D.", 
        "sponsors": {
            "collaborator": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Bhardwaj, Nina, M.D.", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "October 2013"
    }
}